Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Breast Carcinoma: early-phase trial registry
5 of 30 indexed Recurrent Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 5 currently recruiting · #519 of 28,707 conditions by registered trial count
Recurrent Breast Carcinoma: 30 US clinical trials tracked, 5 recruiting.
Recurrent Breast Carcinoma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 15 of these trials.
Enrollment posture brief
Registry condition recurrent-breast-carcinoma
OPEN 5 | RECR 17% | LATE 4 | EARLY 24 | RANK #519 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Recurrent Breast Carcinoma lists 5 open slots (17% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Breast Carcinoma is recruiting below its size-band peers.
5 of 30 indexed trials (16.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Breast Carcinoma research.
National Cancer Institute (NCI) accounts for 15 of 30 trials (50%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Breast Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 30 trials that report a genuine target (sentinel values excluded). 22 of those (73.3%) plan for fewer than 100 participants.
-
Recurrent Breast Carcinoma research is mostly interventional.
28 interventional and 2 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
Mayo Clinic
NCT06217874
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
NCT03418961
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
NCT03971409
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Northwestern University
NCT03213041
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Mayo Clinic
NCT04521764
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
NCT02115282
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
NCT02208375
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02311933
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Mayo Clinic
NCT03281902
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
NCT01327781
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01251874
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI)
NCT04052555
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
University of Washington
NCT02157051
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
NCT01463072
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01351909
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT03939897
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
NCT03941730
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
NCT01275677
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
NCT00785291
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
NCT01349959
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01624441
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
M.D. Anderson Cancer Center
NCT02152943
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
University of Washington
NCT01922921
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT00100750
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Northwestern University
NCT02536794
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
NCT02672475
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02898207
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT01281150
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01575522
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
George W. Sledge Jr.
NCT03364348
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 8 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Breast Carcinoma page
30 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Recurrent Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Breast Carcinoma condition card totals 30 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.